KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Status: | Recruiting |
---|---|
Conditions: | Hematology, Hematology |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/3/2019 |
Start Date: | January 15, 2019 |
End Date: | February 28, 2023 |
Contact: | John Mei |
Email: | jmei@kartosthera.com |
Phone: | 650-542-0136 |
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK Inhibitor
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK
inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
This study is a global, open-label Phase 2 study to determine the efficacy and safety of
KRT-232 in patients with primary MF, post-polycythemia vera MF, or post-essential
thrombocythemia MF who have failed previous treatment with JAK inhibitor (Part A), or
Ruxolitinib (Part B). In Part A of the study, patients will be randomly assigned to 2
different doses and 2 different dosing schedules of KRT-232. In Part B of the study, patients
will be treated at the recommended dose and schedule from Part A.
treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK
inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.
This study is a global, open-label Phase 2 study to determine the efficacy and safety of
KRT-232 in patients with primary MF, post-polycythemia vera MF, or post-essential
thrombocythemia MF who have failed previous treatment with JAK inhibitor (Part A), or
Ruxolitinib (Part B). In Part A of the study, patients will be randomly assigned to 2
different doses and 2 different dosing schedules of KRT-232. In Part B of the study, patients
will be treated at the recommended dose and schedule from Part A.
Inclusion Criteria:
- Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)
- High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System
(DIPSS)
- Failure of prior treatment with JAK inhibitor (Part A) or ruxolitinib (Part B)
- ECOG ≤ 2
Exclusion Criteria:
- Prior splenectomy
- Splenic irradiation within 3 months prior to the first dose of KRT-232
- Active or chronic bleeding within 4 weeks prior to the first dose of KRT-232
- Prior MDM2 inhibitor therapy or p53-directed therapy
- Prior treatment with HDAC or BCL-2 inhibitors
- Grade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version
5.0)
We found this trial at
13
sites
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Phone: 503-346-0227
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-6685
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Gabrail Cancer Center Since 1990, Gabrail Cancer Center has built a national reputation for excellence...
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Phone: 312-996-5931
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
La Jolla, California 92093
Phone: 858-534-5201
Click here to add this to my saved trials
Los Angeles, California 90033
Phone: 323-865-3000
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-362-9236
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials